10-Q: Arteris Inc. Reports Third Quarter 2024 Results: Revenue Growth Amidst Net Loss
Quarterly Report
Arteris Inc. saw a revenue increase in Q3 2024 compared to Q3 2023, but still reported a net loss for the quarter.
Summary
- Arteris Inc. reported a total revenue of $14.7 million for the third quarter of 2024, an increase from $13.3 million in the same period of 2023.
- Licensing, support, and maintenance revenue increased to $13.5 million, up from $12.1 million year-over-year.
- Variable royalties and other revenue saw a slight increase to $1.2 million from $1.19 million.
- The company's net loss for the quarter was $7.7 million, compared to a net loss of $8.2 million in Q3 2023.
- Basic and diluted net loss per share was $0.20, compared to $0.23 in the prior year's quarter.
- For the nine months ended September 30, 2024, total revenue was $42.2 million, up from $41.2 million in the same period of 2023.
- The net loss for the nine-month period was $25.4 million, compared to $26.3 million in the prior year.
- The company's Annual Contract Value (ACV) was $56.4 million as of September 30, 2024, up from $52.3 million in 2023.
- The company had 14 Confirmed Design Starts during the third quarter of 2024.
- Remaining Performance Obligations (RPO) was $78.4 million as of September 30, 2024, up from $62.5 million in 2023.
Sentiment
Score: 5
Explanation: The document presents a mixed picture. While there is revenue growth and an increase in ACV and RPO, the company is still operating at a net loss and faces significant risks. The sentiment is neutral to slightly negative due to the lack of profitability.
Positives
- The company experienced an increase in licensing, support, and maintenance revenue, indicating strong demand for its core offerings.
- The net loss decreased slightly compared to the same quarter last year, suggesting some improvement in financial performance.
- The increase in ACV demonstrates the company's success in expanding its customer base and platform adoption.
- The increase in RPO indicates a growing pipeline of future revenue.
Negatives
- The company continues to operate at a net loss, indicating ongoing challenges with profitability.
- Operating expenses remain high, with total operating expenses exceeding total revenue.
- The company's loss from equity method investment was $0.6 million for the three months ended September 30, 2024, compared to $0.9 million for the three months ended September 30, 2023, representing our proportionate share of Transchips net loss during the three months ended June 30, 2024.
- The company's provision for income taxes was a benefit of $0.1 million for the three months ended September 30, 2024 compared to a benefit of $0.4 million for the three months ended September 30, 2023.
Risks
- The company faces significant competition from larger companies and third-party providers.
- The semiconductor industry is cyclical, which can lead to fluctuations in demand and revenue.
- The company's reliance on a limited number of customers could pose a risk if any of those customers reduce their business.
- The company's international operations are subject to various risks, including regulatory changes and geopolitical instability.
- The company's ability to protect its intellectual property is crucial for its competitive advantage.
- The company is subject to government regulations, including import, export and economic sanctions laws and artificial intelligence regulations that may expose it to liability and increase its costs.
- The company faces risks associated with doing business in China.
Future Outlook
The company believes its cash and cash equivalents, investments, and cash provided by sales will be sufficient to meet its working capital needs for at least the next 12 months. The company expects R&D expenses to increase in absolute terms and as a percentage of revenue in the short term and to continue to increase in absolute terms in the medium to long term but decrease as a percentage of revenue as certain new products are launched. The company expects S&M expenses to increase in absolute terms but decrease as a percentage of revenue due to productivity improvements of our sales processes. The company expects G&A expenses to increase as its business grows and as a percentage of revenue to vary from period to period but generally decrease over the long term.
Management Comments
- The company is taking steps to establish an office in Poland.
- The company monitors ACV to measure its success and believes the increase in the number shows its progress in expanding its customers adoption of its platform.
- The company believes ACV provides investors with useful information to assess the strength and trajectory of its business as growth demonstrates the expansion of customer adoption of its platform.
- The company believes that the number of Confirmed Design Starts is an important indicator of the growth of its business and future royalty revenue trends.
Industry Context
The company operates in the semiconductor IP industry, which is characterized by rapid technological change and intense competition. The demand for sophisticated System IP solutions is growing due to the increasing complexity of SoCs in various markets, including automotive, enterprise computing, communications, consumer electronics, and industrial markets. The company's performance is influenced by the cyclical nature of the semiconductor industry and global economic conditions.
Comparison to Industry Standards
- The company's revenue growth of 11% in Q3 2024 is a positive sign, but its continued net losses indicate that it is still in a growth phase and not yet achieving profitability, which is common for companies in the semiconductor IP space.
- The increase in ACV and RPO suggests that the company is gaining traction in the market and securing future revenue streams, which is a key metric for companies in this industry.
- Compared to larger competitors with more resources, Arteris is still in a position of needing to grow its customer base and market share.
- The company's focus on interconnect IP and SIA solutions aligns with the industry trend towards more complex and integrated chip designs.
- The company's reliance on royalty revenue is typical for IP licensing companies, but it also makes its revenue susceptible to fluctuations in end-product sales.
Legal Proceedings
- On September 4, 2024, the court in the Western District of Texas dismissed all claims against the Company without prejudice in a patent infringement case.
Related Party Transactions
- The company has a lease agreement with Isabelle Geday, a member of the Board of Directors, with lease payments less than $0.1 million for both the three months ended September 30, 2024 and 2023, and $0.1 million for both the nine months ended September 30, 2024 and 2023.
- The company has a consulting agreement with Ms. Geday, paying $0.1 million for both the three and nine months ended September 30, 2024 and 2023.
Stakeholder Impact
- Shareholders may be concerned about the company's continued net losses and the volatility of its stock price.
- Employees may be affected by the company's financial performance and any potential changes in strategy.
- Customers may benefit from the company's continued investment in research and development and its commitment to providing high-quality support.
- Suppliers may be impacted by the company's financial performance and any changes in its procurement policies.
- Creditors may be concerned about the company's ability to repay its debts if it does not achieve profitability.
Next Steps
- The company will continue to invest in research and development to enhance its products and expand its offerings.
- The company will focus on expanding its sales and marketing efforts to acquire new customers and increase market share.
- The company will continue to monitor and manage its international operations and comply with applicable regulations.
- The company will continue to evaluate growth opportunities through acquisitions of other businesses.
Key Dates
| Date | Description |
|---|---|
| April 12, 2004 | Arteris, Inc. was incorporated in Delaware. |
| October 26, 2021 | The company adopted the 2021 Employee Stock Purchase Plan (the 2021 ESPP). |
| May 22, 2024 | The first offering under the 2021 ESPP began. |
| September 4, 2024 | The court in the Western District of Texas dismissed all claims against the Company without prejudice. |
| September 30, 2024 | End of the reporting period for the third quarter results. |
| October 29, 2024 | Date of outstanding shares of the registrants common stock. |
Keywords
semiconductor IP, interconnect IP, System-on-Chip, NoC, licensing, royalties, SIA, Annual Contract Value, design starts, financial results
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.